Attend the FierceBiotech 3rd Drug Development Forum!
The leading executive-level forum for biotech strategy & networking | Oct 1-3 | Boston
Months after losing its hepatitis C collaboration with Janssen, Achillion is trying to cut costs.
Months after raising a $107 million series C, Arcus Biosciences has filed for a $100 million IPO.
Insmed aims to bring a first-in-market therapy to patients in the U.S. suffering from NTM lung disease caused by MAC, a chronic and debilitating condition.
Astellas has bought out a U.S. biotech that wants to ensure cell therapy products aren’t rejected by a patient’s immune system.
Three years after its last misfire, Israeli biotech PolyPid is having another go at a Nasdaq listing, seeking $86 million to develop anti-infectives.
Sarepta expects to resume dosing in a U.K. trial of its DMD drug golodirsen pending MHRA approval.
Nektar Therapeutics could join the growing list of biotechs opting for a takeover, according to a report that it is exploring strategic options.
ReViral has hit its primary and secondary endpoints in a small midstage trial testing its experimental med against RSV.
Buried within Swiss major Roche's fourth-quarter financials was the announcement that it was dumping a host of early- and late-stage candidates.
Solid Bio has pressed on after its plans for an IPO fell apart—with a cut-price offering for an upsized stake.
Eureka Therapeutics will advance its T-cell treatment for relapsed and refractory CD19+ non-Hodgkin lymphoma into the clinic.